Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Neuropsychobiology|August 30, 2017
Plasma BDNF Level in Major Depression: Biomarker of the Val66Met BDNF Polymorphism and of the Clinical Course in Met Carrier PatientsRomain Colle, Séverine Trabado, Denis J David, et al.
Frontiers in Cellular Neuroscience|September 2, 2017
Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety/DepressionIndira Mendez-David, Céline Boursier, Valérie Domergue, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 17, 2013
Huntingtin mediates anxiety/depression-related behaviors and hippocampal neurogenesisKarim Ben M'Barek, Patrick Pla, Sophie Orvoen, et al.
Neuroscience Letters|April 29, 2015
Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depressionIndira Mendez-David, Laurent Tritschler, Zeina El Ali, et al.
British Journal of Pharmacology|January 12, 2012
Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in miceHai T Nguyen, Bruno P Guiard, Alexandre Bacq, et al.
Journal of Affective Disorders|January 2, 2019
Methemoglobinemia as a biomarker of dapsone-induced mania severityRomain Colle, Abd El Kader Ait Tayeb, Pierre Mesdom, et al.
Fundamental & Clinical Pharmacology|July 16, 2025
Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular MechanismsMakiath Adebo, Mathilda Bonnet, Ons Laouej, et al.
Pharmacogenomics|March 1, 2017
No impact of eight NTRK2 genetic polymorphisms on 6-month antidepressant efficacy in depressed patientsEric Deflesselle, Céline Verstuyft, Anne-Cécile Petit, et al.
Neuropharmacology|March 2, 2011
Modeling treatment-resistant depressionBenjamin Adam Samuels, Eduardo David Leonardo, Reto Gadient, et al.
Fundamental & Clinical Pharmacology|May 10, 2023
Intrahippocampal injection of a selective blocker of NMDA receptors containing the GluN2B subunit, Ro25-6981, increases glutamate neurotransmission and induces antidepressant-like effectsJulie Doan, Céline Defaix, Indira Mendez-David, et al.
Pageof 9